Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-escalation Sequention Cohort Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNR-084 in Patients With Refractory or Relapse Acute Lymphoblastic B-cell Precursor Leukemia.

NCT04601584 is registered in ClinicalTrials.gov with AO GENERIUM as lead sponsor.

NCT NCT04601584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04601584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-escalation Sequention Cohort Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNR-084 in Patients With Refractory or Relapse Acute Lymphoblastic B-cell Precursor Leukemia.
Lead sponsor
AO GENERIUM
Phase
Phase 1/2
Overall status
Terminated
Start date
October 15, 2020
Completion date
December 18, 2024
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

all, b-precursor acute lymphoblastic leukemia, gnr-084